Last updated: 2026-09-09 04:29:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Fate Therapeutics, Inc. (FATE) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.50, with a market capitalization of $297.15M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.93 to $3.23. This page covers its latest market performance, valuation, price trends and company information.
$297.15M | |
$2.45 | |
$121.16 | |
$0.66 | |
$2.48 | |
1.88M | |
2.85M | |
-- | |
$3.23 | |
$0.93 | |
-- | |
-- |
Fate Therapeutics, Inc. (FATE) last closed at $2.48 as of 2026-09-08 23:31:00, unchanged from the previous close of $2.48.
During the latest regular trading session, FATE traded between $0.66 and $121.16, with a volume of 1.88M shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Fate Therapeutics, Inc. (FATE) moved from $2.54 to $2.50, representing a decline of 1.77% ($0.04).
The stock traded between $2.34 and $2.60 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 918.04 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 68.0%
FATE is currently trading at $2.50, placing it 68.0% of the way from its 52-week low of $0.93 to its 52-week high of $3.23. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 161 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Fate Therapeutics, Inc. (FATE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.